Litigation Details for (EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)
✉ Email this page to a colleague
(EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-06-21 |
| Court | District Court, E.D. Virginia | Date Terminated | 2019-05-07 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Rebecca Beach Smith |
| Jury Demand | Plaintiff | Referred To | Douglas E. Miller |
| Patents | 7,030,106; 7,612,058; RE37,721 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in (EPP)Self Insured Schools of California v. Merck and Co Inc
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for (EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-03-23 | 1 | issued as U.S. 4 Patent No. 7,030,106. According to Merck, the ’106 patent originally was set to …U.S. Patent No. 5,631,365 (“the ’365 15 patent”), U.S. Patent No. 5,767,115 (“the ’115 patent”), U.S… U.S. Patent No. 5,846,966 16 (“the ’966 patent”), the RE’721 reissue patent, and the RE’461 reissue… U.S. Patent No. 5,631,365. The ’365 patent was the first-issued 19 Merck azetidinone patent. The …. On May 28, 2002, the Patent 2 Office re-issued the patent as U.S. Patent No. RE37,721. 3 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
